Increase/Decrease in Cash (Quarterly)

Increase/Decrease in Cash: The total change in cash for the company over the given period.

ADMA Biologics Inc (ADMA) had Increase/Decrease in Cash of $-31.52M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$114.80M
Net Income	$26.90M
Cost of Goods Sold	$53.70M
Gross Profit	$61.10M
Operating Expenses	$79.92M
Operating Income	$34.88M
Non-Operating Income/Expense	$-1.43M
Pre-Tax Income	$33.45M
Normalized Pre-Tax Income	$33.45M
Income after Taxes	$26.90M
Income from Continuous Operations	$26.90M
Consolidated Net Income/Loss	$26.90M
Normalized Income after Taxes	$26.90M
EBIT	$34.88M
EBITDA	$37.00M
Weighted-Average Shares Outstanding (Basic)	237.78M
Weighted-Average Shares Outstanding (Diluted)	244.68M
Earnings per Share (EPS) (Basic)	$0.11
Earnings per Share (EPS) (Diluted)	$0.11
Balance Sheet Financials
Current Assets	$351.81M
Property, Plant, and Equipment	$57.71M
Long-Term Assets	$158.75M
Total Assets	$510.57M
Current Liabilities	$53.50M
Long-Term Debt	$80.83M
Long-Term Liabilities	$83.65M
Total Liabilities	$137.15M
Common Equity	$373.42M
Tangible Shareholders Equity	$369.44M
Shareholders Equity	$373.42M
Common Shares Outstanding	238.53M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-19.68M
Cash Flow from Investing Activities	$-4.72M
Cash Flow from Financial Activities	$-7.13M
Beginning Cash	$103.15M
End Cash	$71.62M
Increase/Decrease in Cash	$-31.52M
Stock-Based Compensation	$4.62M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.58
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.18
Debt to Equity Ratio	0.22
Gross Margin	53.22%
Operating Margin	30.38%
EBIT Margin	30.38%
EBITDA Margin	--
Pre-Tax Profit Margin	29.14%
Profit Margin	23.44%
Free Cash Flow	$-24.38M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.31
Receiveable Turnover	1.15
Days Sales in Receivables	77.93
Return on Equity	7.20%
Return on Tangible Equity	7.28%
Return on Assets	5.27%
Return on Investments	5.92%
Book Value Per Share	$1.57
Free Cash Flow per Share	$-0.10
Operating Cash Flow per Share	$-0.08

Data from Zacks Investment Research, Inc.